1. Inicio
  2. Publicaciones
  3. Time for radioimmunotherapy: an overview to bring improvements in clinical practice

Time for radioimmunotherapy: an overview to bring improvements in clinical practice

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Alcibar, OL
  • Candini, D
  • Lopez-Campos, F
  • Antequera, MA
  • Macias, VM
  • Perez, AR
  • Moron, AH
  • Martinez, JC
  • Albiach, CF
  • Aguilar, SN
  • Rodriguez-Ruiz, ME

Abstract

Harnessing the patient's own immune system against an established cancer has proven to be a successful strategy. Within the last years, several antibodies blocking critical checkpoints that control the activation of T cells, the immune cells able to kill cancer cells, have been approved for the use in patients with different tumours. Unfortunately, these cases remain a minority. Over the last years, radiotherapy has been reported as a means to turn a patient's own tumour into an in situ vaccine and generate anti-tumour T cells in patients who lack sufficient anti-tumour immunity. Indeed, review data show that the strategy of blocking multiple selected immune inhibitory targets in combination with radiotherapy has the potential to unleash powerful anti-tumour responses and improve the outcome of metastatic solid tumours. Here, we review the principal tumours where research in this field has led to new knowledge and where radioimmunotherapy becomes a reality.

Datos de la publicación

ISSN/ISSNe:
1699-048X, 1699-3055

Clinical & Translational Oncology  SPRINGER INT PUBL AG

Tipo:
Review
Páginas:
992-1004
PubMed:
30644044
Factor de Impacto:
0,833 SCImago ℠
Cuartil:
Q2 SCImago ℠

Citas Recibidas en Web of Science: 13

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Abscopal effect; Radiotherapy; Radioimmunotherapy; Immunotherapy combinations; Immunogenic neoplasms

Campos de Estudio

Compartir